The aim of the study was to assess the patterns of development of metachronous cancer (endometrial cancer, EC, and ovarian cancer, OC) in breast cancer (BC) patients dependent of receptor phenotype of breast tumors. In the study, 63 patients with BC, who developed metachronous EC (n = 47) or OC (n = 16) were enrolled. Expression of estrogen receptor (ER), progesterone receptor (PR), HER/2neu was assessed using immunohistochemical approach. BC in patients with metachronous EC and OC was characterized by a different frequency of molecular subtypes with the dominance of luminal A (36 %) and B (43 %) subtypes. In primary BC, we have established a correlation between ER expression and regional lymph nodes status (r = -0,50, p << 0,05); negative correlation between HER2/neu expression and tumor stage (r = -0,48, p << 0,05); between the molecular subtype of BC and its size (r = -0,33, p << 0,05), the molecular subtype of primary BC and metastases in regional lymph nodes (r = 0,27, p << 0,05). In the patients with luminal subtype BC metachronous tumors developed with the highest frequency (OC - 50 %, EC - 50 %). After treatment of primary BC metachronous tumors developed at different period: EC (22,2 %) - most often in 3 - 5 years, OC (11,0 %) - after 10 years and more. Conclusion: our data evidence on the clinical significance of the individual characteristics of the BC, especially its molecular subtype, and the need to calculate the personalized risk of development of metachronous tumors of the reproductive system in patients with the BC.

  Якщо, ви не знайшли інформацію про автора(ів) публікації, маєте бажання виправити або відобразити більш докладну інформацію про науковців України запрошуємо заповнити "Анкету науковця"